You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 20, 2024

CLINICAL TRIALS PROFILE FOR TENECTEPLASE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for tenecteplase

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00064428 ↗ OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction Completed Sanofi Phase 3 2003-08-01 This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.
NCT00064428 ↗ OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction Completed GlaxoSmithKline Phase 3 2003-08-01 This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed Eli Lilly and Company Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed Hoffmann-La Roche Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed Sanofi Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗ Which Therapy for Acute Heart Attacks? (The WEST Study) Completed University of Alberta Phase 2/Phase 3 2003-07-01 In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00148460 ↗ Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction Completed Boehringer Ingelheim Phase 3 2001-03-01 The objective of this trial was to compare the efficacy and safety of a single bolus of TNK-tPA (tenecteplase, Metalyse®) compared with rt-PA (alteplase, Actilyse®) in Asian patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for tenecteplase

Condition Name

Condition Name for tenecteplase
Intervention Trials
Ischemic Stroke 14
Myocardial Infarction 12
Acute Ischemic Stroke 9
Stroke 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for tenecteplase
Intervention Trials
Stroke 40
Ischemic Stroke 37
Ischemia 24
Myocardial Infarction 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for tenecteplase

Trials by Country

Trials by Country for tenecteplase
Location Trials
China 89
United States 63
Australia 31
Canada 29
United Kingdom 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for tenecteplase
Location Trials
California 5
Georgia 4
Massachusetts 4
Michigan 4
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for tenecteplase

Clinical Trial Phase

Clinical Trial Phase for tenecteplase
Clinical Trial Phase Trials
Phase 4 6
Phase 3 38
Phase 2/Phase 3 9
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for tenecteplase
Clinical Trial Phase Trials
Completed 23
Not yet recruiting 20
Recruiting 18
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for tenecteplase

Sponsor Name

Sponsor Name for tenecteplase
Sponsor Trials
Boehringer Ingelheim 14
Genentech, Inc. 12
Beijing Tiantan Hospital 6
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for tenecteplase
Sponsor Trials
Other 130
Industry 40
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.